BioCardia

BioCardia Receivables

Accounts Receivable of BioCardia (BCDA) as of Nov 20, 2026.

Receivables

0.00USD

Last updated:

Accounts Receivable of BioCardia is 2024 0.00 USD. Accounts Receivable of BioCardia was 2023 63,000.00 USD. It decreases by % lower compared to the previous year.

The BioCardia Receivables history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Receivables
Date
Receivables
Jan 1, 2017
100,000.00 USD
Jan 1, 2018
270,000.00 USD
Jan 1, 2019
150,000.00 USD
Jan 1, 2020
230,000.00 USD
Jan 1, 2021
150,000.00 USD
Jan 1, 2022
200,000.00 USD
Jan 1, 2023
63,000.00 USD
Jan 1, 2024
0.00 USD
The BioCardia Receivables history
YEARReceivablesYoY
0.00USD-100.00%
63,000.00USD-68.50%
200,000.00USD+33.33%
150,000.00USD-34.78%
230,000.00USD+53.33%
150,000.00USD-44.44%
270,000.00USD+170.00%
100,000.00USD+42.86%
70,000.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioCardia Stock analysis

What does BioCardia do? BioCardia, Inc. generates revenue through its clinical-stage regenerative medicine portfolio, primarily focused on CardiAMP and CardiALLO cell therapies. The CardiAMP Cell Therapy System is in Phase III trials for ischemic systolic heart failure, targeting healthcare providers and clinical trial sponsors seeking advanced treatments for heart failure patients. CardiALLO, an allogeneic off-the-shelf mesenchymal stem cell product, is developed for broader therapeutic applications, appealing to hospitals and research institutions requiring ready-to-use regenerative solutions. The company also monetizes the Helix Biotherapeutic Delivery System and Morph Deflectable Guide and Sheaths Products, which serve as complementary tools for medical professionals during therapeutic procedures. CardiAMP and CardiALLO are positioned as innovative therapeutic candidates targeting heart failure and regenerative medicine segments, with CardiAMP advancing toward potential commercialization in late-stage trials. The Helix Biotherapeutic Delivery System and Morph Deflectable Guide and Sheaths Products cater to interventional cardiology and surgical markets, providing specialized equipment for clinicians. BioCardia's revenue streams are derived from partnerships with clinical trial sponsors and direct sales of medical devices to healthcare facilities, focusing on cardiovascular and regenerative medicine applications. The company's business model relies on developing and commercializing cell therapies and medical devices, with CardiAMP leading the portfolio in late-stage development. CardiALLO serves as a complementary allogeneic product, while the Helix and Morph products support procedural needs in cardiology. Revenue is anticipated from future commercialization of CardiAMP post-trial success and from ongoing sales of the Helix and Morph systems to medical institutions. BioCardia is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioCardia stock

On Eulerpool you can find the complete historical development of Accounts Receivable BioCardia since 2006 – with annual values, charts, and detailed analysis.

Receivables represent money owed to the company by customers for goods or services delivered. High receivables relative to revenue may indicate collection issues.

Accounts Receivable's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Accounts Receivable's BioCardia historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — BioCardia

All Key Metrics — BioCardia